Dr. Uday Devgan has joined the ExSight Ventures team as an advisor. Professor Uday Devgan, M.D. is a renowned Los Angeles cataract surgeon, recognized for teaching at UCLA, and author of the widely followed CataractCoach.com TM. Dr. Devgan will provide a valuable resource to both the ExSight Ventures team and our portfolio companies.

The most recent installment of the Ophthalmology Innovation Showcase (OIS XIII) in San Diego put a spotlight on the remarkable breakthroughs occurring in ophthalmology that are poised to redefine eye care. ExSight Ventures co-founder Dr. Firas Rahhal co-chaired while James Murray participated in a panel discussion. ExSight Ventures portfolio companies featured prominently as well. Let's jump into key highlights from the meeting.

ExSight Ventures 2023 year in review. We highlight notable achievements in ophthalmic innovation.

ExSight Ventures Announces 60% Increase for Ophthalmology Focused Venture Fund with Participation from a leading eye care foundation

Reflecting on summer 2022 meetings with portfolio companies and friends in New York City.

ExSight portfolio company DTx Pharma acquired by Novartis for $500 Million upfront.

ExSight portfolio companies LensGen, Trefoil, and Elios all presented during the 2023 ASCRS Annual Meeting in San Diego.

On this episode of the OIS Podcast ExSight’s co-founder, Dr. Firas Rahhal, sits down with Gianluca Rossetti, Strategic Planning & Corporate Business Development Director at Dompé. The two discuss Dompé’s storied 130-year history, keys to surviving and succeeding global challenges, views to the future, and the all-or-nothing nature of drug development.

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

ExSight Ventures is pleased to announce our recent investment into Novai, a cutting-edge biotech company developing innovative solutions for the detection and treatment of retinal diseases.

Re-Vana Therapeutics Ltd. announces oversubscribed $11.9 million Series A round. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™, and OcuLief® biodegradable drug delivery technologies

Envision Diagnostic’s device will bring eye care into the 21st Century with quantified, standardized examinations. Envision is the future of eye care.

ExSight participates in Valitor’s $28 million Series B to fund Multivalent Polymer (MVP) technology platform’s development.

EXSIGHT VENTURES OPENS ITS SYNDICATE TO THE OIS COMMUNITY

Reflecting on summer 2022 meetings with portfolio companies and friends in New York City.

ONWARD! ONL HITS MILESTONES AND ACHIEVES TRANCHE 2 FUNDING OF $46.9 MILLION SERIES B

OIS YEAR IN REVIEW

CONGRATULATIONS TO LENSGEN TEAM ON THIS SIGNIFICANT MILESTONE: IDE APPROVAL FROM THE U.S. FDA TO BEGIN CLINICAL STUDY

ELT SIGHT: TAKING "MINIMALLY INVASIVE" GLAUCOMA SURGERY TO NEW HEIGHTS

TREFOIL PROFILED IN OPHTHALMOLOGY BIOPHARMA DEALMAKERS